Humanigen, Inc. (NASDAQ:HGEN) Receives $24.75 Average Price Target from Analysts

Humanigen, Inc. (NASDAQ:HGEN – Get Rating) has received a consensus recommendation of “Hold” from the eight research firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $24.75.

Separately, Zacks Investment Research raised shares of Humanigen from a “sell” rating to a “hold” rating in a research report on Thursday, February 24th.

In other news, insider Dale Chappell bought 1,000,000 shares of the firm’s stock in a transaction on Friday, March 11th. The shares were purchased at an average cost of $3.00 per share, with a total value of $3,000,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Edward P. Jordan purchased 12,500 shares of Humanigen stock in a transaction dated Wednesday, March 2nd. The stock was bought at an average price of $2.32 per share, for a total transaction of $29,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 1,059,500 shares of company stock worth $3,140,310. Insiders own 37.50% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of HGEN. Morgan Stanley boosted its stake in shares of Humanigen by 1,884.6% in the 2nd quarter. Morgan Stanley now owns 128,841 shares of the company’s stock valued at $2,239,000 after purchasing an additional 122,349 shares in the last quarter. Royal Bank of Canada boosted its stake in shares of Humanigen by 44.2% in the 2nd quarter. Royal Bank of Canada now owns 9,950 shares of the company’s stock valued at $172,000 after purchasing an additional 3,050 shares in the last quarter. Invesco Ltd. acquired a new stake in shares of Humanigen in the 2nd quarter valued at approximately $260,000. Wells Fargo & Company MN boosted its position in Humanigen by 22.4% during the 2nd quarter. Wells Fargo & Company MN now owns 3,675 shares of the company’s stock worth $64,000 after buying an additional 673 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in Humanigen during the 3rd quarter worth approximately $108,000. Institutional investors own 39.37% of the company’s stock.

Shares of HGEN opened at $2.46 on Tuesday. The company’s 50-day moving average is $2.67 and its 200-day moving average is $4.21. Humanigen has a fifty-two week low of $1.67 and a fifty-two week high of $23.53.

Humanigen (NASDAQ:HGEN – Get Rating) last issued its quarterly earnings data on Monday, February 28th. The company reported ($0.53) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.09. The company had revenue of $1.04 million for the quarter, compared to analyst estimates of $1.01 million. Humanigen had a negative net margin of 6,582.73% and a negative return on equity of 4,882.88%. Equities research analysts anticipate that Humanigen will post -1.33 EPS for the current fiscal year.

Humanigen Company Profile (Get Rating)

Humanigen, Inc, a clinical stage biopharmaceutical company, develops a portfolio of anti-inflammatory immunology and immuno-oncology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which has completed Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that is in Phase II clinical trial in patients with chronic myelomonocytic leukemia.

Featured Articles